Please Wait.....
Report
Kidney Cancer Therapeutics and Diagnostics Market by Component (Drugs, Diagnostics), Cancer Types (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, and Others), Application (Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others), and Region 2023-2028
Market Report I 2023-05-29 I 142 Pages I IMARC Group
The global kidney cancer therapeutics and diagnostics market size reached US$ 4.72 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.17 Billion by 2028, exhibiting a growth rate (CAGR) of 7.12% during 2023-2028. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.
Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.
Kidney Cancer Therapeutics and Diagnostics Market Trends:
The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global kidney cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on component, cancer types, and application.
Component Insights:
Drugs
Drugs by Therapeutic Class
Targeted Therapy
Immunotherapy
Others
Drugs by Pharmacologic Class
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (II-2)
Diagnostics
Imaging Test
Biopsy
Blood Test
Others
The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2))) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.
Cancer Types Insights:
Clear Cell RCC
Papillary RCC
Chromophobe RCC
Transitional Cell Carcinoma
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the cancer types has been provided in the report. This includes clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. According to the report, clear cell RCC accounted for the largest market share.
Application Insights:
Hospitals
Pharmaceutical Labs
Genomic Laboratories
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the application has been provided in the report. This includes hospitals, pharmaceutical labs, genomic laboratories, and others. According to the report, hospitals accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global kidney cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global kidney cancer therapeutics and diagnostics market?
What are the key regional markets?
Which countries represent the most attractive kidney cancer therapeutics and diagnostics markets?
What is the breakup of the market based on the component?
What is the breakup of the market based on the cancer types?
What is the breakup of the market based on the application?
What is the competitive structure of the global kidney cancer therapeutics and diagnostics market?
Who are the key players/companies in the global kidney cancer therapeutics and diagnostics market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Kidney Cancer Therapeutics and Diagnostics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Component
6.1 Drugs
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Drugs by Therapeutic Class
6.1.2.1.1 Targeted Therapy
6.1.2.1.2 Immunotherapy
6.1.2.1.3 Others
6.1.2.2 Drugs by Pharmacologic Class
6.1.2.2.1 Angiogenesis Inhibitors
6.1.2.2.2 mTOR Inhibitors
6.1.2.2.3 Monoclonal Antibodies
6.1.2.2.4 Cytokine Immunotherapy (II-2)
6.1.3 Market Forecast
6.2 Diagnostics
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Imaging Test
6.2.2.2 Biopsy
6.2.2.3 Blood Test
6.2.2.4 Others
6.2.3 Market Forecast
7 Market Breakup by Cancer Types
7.1 Clear Cell RCC
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Papillary RCC
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Chromophobe RCC
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Transitional Cell Carcinoma
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Application
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pharmaceutical Labs
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Genomics Laboratories
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Bristol-Myers Squibb Company
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Exelixis Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Genentech Inc. (Roche Holding AG)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 SWOT Analysis
14.3.4 Novartis AG
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Pfizer Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT AnalysisKindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2022
Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2022
Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2022
Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2022
Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2022
Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis
Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million US$), 2023-2028
Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million US$), 2023-2028
Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security